Zenshine’s Phase ll influenza therapy trial meets primary endpoint

Nanjing Zenshine Pharmaceuticals has reported that its Phase ll trial of ZX-7101A to treat acute uncomplicated influenza in adults met the primary endpoint.

The company’s anti-influenza agent ZX-7101A demonstrated successful safety and efficacy profiles.